Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2006 by Rabin Medical Center.
Recruitment status was Not yet recruiting

Sponsor:

Information provided by:

Rabin Medical Center

ClinicalTrials.gov Identifier:

NCT00418249

First received: January 2, 2007

Last updated: January 3, 2007

Last verified: December 2006

History of Changes

Purpose

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Condition	Intervention	Phase
Alopecia	Drug: AS101	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Resource links provided by NLM:

Genetics Home Reference related topics: androgenetic alopecia

MedlinePlus related topics: Menopause

U.S. FDA Resources

Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:

hair density

Secondary Outcome Measures:

Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,
Self-administered satisfaction questionnaire


Estimated Enrollment:	40

Eligibility


Ages Eligible for Study:	50 Years and older (Adult, Senior)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Women in menopause, over 50 years of age.
Clinically diagnosed for AGA, according to Ludwig scale I-II.

Exclusion Criteria:

Women treated with chronic medications.
Use of Minoxidil within 3 months prior to entering study.
Women who have underwent hair transplantation.
Use of drugs with androgenic or anti-androgenic effects.
Any other type of hair loss.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00418249

Contacts


Contact: Danny Ben Amitai, MD	972-3-9253770
Contact: Raziel Lurie, MD		rlurie@bezeqint.net

Locations


Israel
	Not yet recruiting
Tel Aviv, Israel
Contact: Danny Ben Amitai 972-3-9253770

Sponsors and Collaborators

Rabin Medical Center

Investigators


Principal Investigator:	Danny Ben-Amitai, M.D.	Rabin Medical Center

More Information


ClinicalTrials.gov Identifier:	NCT00418249 History of Changes
Other Study ID Numbers:	#69 REV 00
Study First Received:	January 2, 2007
Last Updated:	January 3, 2007
Health Authority:	Israel: Ministry of Health

Keywords provided by Rabin Medical Center:


Androgenetic Alopecia Telogen effluvium Chronic telogen effluvium Menopause Female Androgenetic Alopecia (FAGA)

Additional relevant MeSH terms:


Hair Diseases Alopecia Alopecia Areata Hypotrichosis Skin Diseases Pathological Conditions, Anatomical Ammonium trichloro(dioxoethylene-O,O'-)tellurate Adjuvants, Immunologic	Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Antiviral Agents Anti-Infective Agents Radiation-Protective Agents Protective Agents

ClinicalTrials.gov processed this record on September 28, 2016

To Top